GlassScriptPhysician profile
Narottam Regmi
NPI 1427347947
$11,994.24
in general payments reported to CMS, 2019-2025
36 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $1,149 · 2021: $2,381 · 2022: $1,884 · 2023: $1,693 · 2024: $1,713 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347 · Education: $1.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.75 |
| Education | $1.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,817.14 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,498.75 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Baxter Healthcare | $969.98 | 2019-2024 | Renal - Prismax System, Renal - Acute, Renal - Pd |
| Daiichi Sankyo INC. | $807.38 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $745.86 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $695.15 | 2019-2024 | Rayaldee |
| Vifor Pharma, INC. | $605.19 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $451.53 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $436.95 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $410.83 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $294.67 | 2022-2025 | Tarpeyo |
| Allergan, INC. | $287.08 | 2019 | |
| Pharmacosmos Therapeutics INC. | $277.86 | 2021-2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.14 | 2023-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $237.23 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $221.28 | 2019-2023 | Envarsus |
| Glaxosmithkline, LLC. | $212.89 | 2020-2025 | Benlysta |
| Vantive US Healthcare LLC | $212.63 | 2025 | Renal - Acute, Renal - Pd |
| Novo Nordisk INC | $211.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $171.75 | 2021-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $138.04 | 2020-2025 | Terlivaz |
| Travere Therapeutics, INC. | $127.82 | 2025 | Filspari |
| Akebia Therapeutics INC | $121.64 | 2020-2022 | |
| Ardelyx, INC. | $117.40 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Janssen Pharmaceuticals, INC | $105.02 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2019 | |
| Horizon Therapeutics Plc | $95.05 | 2022-2023 | Krystexxa |
| Cormedix INC. | $76.28 | 2024-2025 | Defencath |
| Ani Pharmaceuticals, INC. | $58.76 | 2022-2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $55.63 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $37.09 | 2025 | Empaveli |
| Nuwellis, INC. | $28.65 | 2020 | |
| Smith+Nephew, INC. | $28.12 | 2020 | |
| Scpharmaceuticals INC. | $25.29 | 2025 | |
| Pfizer INC. | $24.76 | 2019 | |
| Abbott Laboratories | $21.98 | 2025 | Cardiomems |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narottam Regmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.